Draft Agenda: 3/11/2004
BLOOD PRODUCTS ADVISORY COMMITTEE
79th
Meeting – March 18-19, 2004
Gaithersburg,
MD 20877
Thursday, March 18, 2004
8:00 a.m. Welcome, Statement of
Conflict of Interest, Announcements
8:05
a.m. Open Committee Discussion
I.
Clinical Trials for Licensing Hepatitis B Immune Globulin Intravenous as
Treatment to Prevent HBV Liver Disease Following Liver Transplantation in HBV+
Recipients (3.5 hrs)
A. Introduction
and Background – Basil Golding, MD, Director, Division of Hematology, OBRR
(15’)
B. Presentation
– Anna Lok, MD (70’)
9:30 a.m.
OPEN PUBLIC HEARING
10:00
a.m. BREAK
10:30
a.m. Open Committee Discussion
C. FDA Current Thinking and Questions for the Committee
D. Committee Discussion and Recommendations
11:15
a.m. Committee Updates
·
Current Thinking on Variances to Address the
Specificity Issues of Ortho HBsAg 3.0 Assays – Gerardo Kaplan, PhD (15’)
·
Summary of Meeting of PHS Advisory Committee on
Blood Safety Availability – Jerry Holmberg, MD (15’)
·
Summary of Meeting of Transmissible Spongiform
Encephalopathies Advisory Committee Meeting – David Asher, MD (15’)
·
Current Thinking on Draft Guidance for Nucleic Acid
Testing (NAT) for HIV and HCV: Testing,
Product Disposition, and Donor Deferral and Re-entry – Paul Mied, PhD (15’)
·
Current Thinking on Final Guidance for Use of
Nucleic Acid Testing (NAT) on Pooled and Individual Samples from Donors of
Whole Blood and Blood Components to Adequately and Appropriately Reduce the
Risk of Transmission of HIV-1 and HCV – Indira Hewlett, PhD (15’)
12:30
p.m. LUNCH
1:30 p.m.
Open Committee Discussion
II.
Supplemental Testing for Human Immune Deficiency Virus (HIV) and Hepatitis C
Virus (HCV) (3.5 hrs)
A.
Introduction and Background – Robin Biswas, MD and
Indira Hewlett, PhD, DETTD, OBRR, FDA
B.
Performance of HIV and HCV Supplemental Assays
2. Susan Stramer, PhD, ARC – 20’
3:30
p.m. BREAK
3:45
p.m. OPEN PUBLIC HEARING
4:15 p.m.
Open Committee Discussion
C.
Questions for the Committee
D.
Committee Discussion and Recommendations
5:00 p.m.
RECESS (8:00 a.m. Friday, March 19, 2004)
Friday,
March 19, 2004
8:00
a.m. Open Committee Discussion (3.5
hrs)
A. Introduction and Background – Alan E. Williams, PhD, Director, Division of Blood Applications, OBRR
B. FDA Current Thinking: Product Standards, Quality Assurance and Submission Requirements - Sharyn Orton, PhD
E.
Blood Center Perspective on
Plateletpheresis Quality Control – German Leparc, MD, Florida Blood
Services
9:30 a.m.
OPEN PUBLIC HEARING
10:00
a.m. BREAK
10:30
a.m. Open Committee Discussion
F. FDA Current Thinking and Questions
for the Committee
G. Committee Discussion and Recommendations
11:30
a.m. LUNCH
12:30
p.m. Open Committee Discussion
IV.
Review of Site Visit of the Laboratory of Hepatitis and Related Emerging Agents
and the Laboratory of Bacterial, Parasitic, and Unconventional Agents, Division
of Emerging and Transfusion Transmitted Diseases, OBRR, CBER
2:15 p.m.
CLOSED SESSION
3:00 p.m.
ADJOURNMENT